User menu

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.

Bibliographic reference Zhu, Andrew X ; Park, Joon Oh ; Ryoo, Baek-Yeol ; Yen, Chia-Jui ; Poon, Ronnie ; et. al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.. In: The Lancet Oncology, Vol. 16, no. 7, p. 859-870 (2015)
Permanent URL http://hdl.handle.net/2078.1/172108